Psilocybin

A new pilot study suggests that combining the psychedelic compound psilocybin with cognitive behavioral therapy is well-tolerated and highly effective at reducing symptoms of clinical depression. Researchers observed profound improvements in patients' moods and emotional regulation.

A major national survey reveals that 2.8% of Americans over the age of 12 used psilocybin in 2024. The study found strong links between magic mushroom use, cannabis consumption, and recent struggles with depression.

New research shows that psilocybin, the active compound in magic mushrooms, reduces chronic nerve pain in mice. It also significantly enhances the performance of common pain drugs, suggesting the psychedelic might fundamentally rewire how the brain processes pain.

A new study reveals that a rodent's age and reproductive cycle strongly influence its response to psilocybin, pointing toward a need for customized psychiatric drug treatments across different patient demographics.

A single high dose of psilocybin can cause lasting physical changes in the human brain. Scientists found that temporary increases in brain randomness during the experience predict improved well-being and mental flexibility for at least a month.

A single dose of psilocybin paired with behavioral therapy proved remarkably effective at helping cigarette smokers quit. A new clinical trial shows the psychedelic intervention substantially outperformed standard nicotine patches over a six-month tracking period.

A new clinical trial suggests that repeated doses of psilocybin can safely reduce symptoms of obsessive-compulsive disorder. The findings provide evidence that multiple weekly treatments offer lasting relief for those struggling with traditional therapies.

A quick scan of your resting brain waves might hold the secret to predicting how intensely you will react to psilocybin, offering doctors a potential new tool for personalizing psychedelic therapy.

Recent research is dampening the hype around psychedelic therapy. By adjusting for how clinical trials are designed, scientists found that drugs like LSD and psilocybin offer similar depression relief to traditional antidepressants, rather than vastly superior results.

A new analysis reveals that psilocybin temporarily slows down human reaction times and mildly impairs executive functions. The findings highlight the need for safety protocols as psychedelic therapies move closer to widespread clinical acceptance.

A recent trial involving healthy volunteers demonstrates that a single dose of psilocybin can prompt lasting changes in personal values, increasing self-acceptance and appreciation for life through acute feelings of spiritual euphoria and profound unity.

A placebo-controlled experiment reveals how psilocybin changes human time perception. By testing volunteers on a visual timing task, researchers found the psychedelic compound causes people to underestimate durations and feel time passing much slower than normal.

Clinical trials show psilocybin provides rapid relief for depression, but the underlying biology remains unclear. New research demonstrates how varying doses of the drug bind to serotonin receptors to enhance cellular flexibility.

New research suggests that psilocybin shifts the brain from a relaxed state into a highly engaged pattern of rapid electrical activity. This measurable shift in brain waves provides evidence linking biological changes directly to subjective psychedelic experiences.

Published in Scientific Reports, new research provides evidence that minor compounds in psychedelic mushrooms work alongside psilocybin to interact with brain receptors. This chemical teamwork explains why whole mushroom extracts often affect people differently than isolated, lab-made psilocybin.